Rakovina Therapeutics Presents New Preclinical Data at AACR 2026 Annual Meeting Life Science Investing
Lexaria Bioscience: Drug Delivery Platform Innovator with Multiple Mainstream Applications Biotech Investing
Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026 Life Science Investing
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting Life Science Investing
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation Life Science Investing
Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting Life Science Investing
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology Annual Meeting Life Science Investing
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer
